INNATE PHARMA: First-in-class CD39 checkpoint inhibitor presented at the AACR meeting
Novel, potent anti-CD39 antibody, IPH52, validated in preclinical models. MARSEILLE, France and LYON, France, April 19, 2016 (GLOBE NEWSWIRE) -- Innate Pharma and OREGA Biotech today presented preclinical data on IPH52, a new CD39 checkpoint inhibitor …